For Research Use Only. Not for human consumption. The following summarizes published preclinical literature for laboratory research purposes only.
What It Is
TB-500 is a synthetic fragment/analog of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid regulatory protein found in nearly all human and animal cell types. Tβ4 belongs to the beta-thymosin family of actin-binding proteins, meaning its primary described biochemical role is sequestering G-actin monomers, which influences cell motility and cytoskeletal dynamics (Clinical Ophthalmology review). TB-500 refers to the shorter, stabilized synthetic peptide sequence used in laboratory research settings to approximate the bioactive region of the full Tβ4 protein.
Summary of Published Preclinical Research
A 2013 rat study published in Regulatory Peptides examined surgically transected medial collateral ligaments (MCL) treated locally with Tβ4 delivered via fibrin sealant. Histological analysis at four weeks showed more uniform, evenly spaced collagen fiber bundles and significantly increased collagen fibril diameter in the Tβ4-treated group compared to controls, and biomechanical testing found significantly higher tensile properties in treated ligament-bone complexes (Regulatory Peptides, 2013, PMID 23523891).
Corneal wound-healing research is another major branch of the Tβ4 literature. A review in Clinical Ophthalmology consolidates multiple animal studies, including heptanol-debridement and alkali-burn corneal injury models in which Tβ4 accelerated re-epithelialization and reduced post-injury inflammation, with treated corneas showing more normal anatomical integrity and increased hemidesmosomal adhesion at the basement membrane compared to controls (Clinical Ophthalmology). The same review notes Tβ4 promoted full-thickness dermal wound repair in normal, steroid-treated, and diabetic animal models, referencing foundational work by Malinda et al. (1999) and Philp et al. (2003).
Separately, cardiac regeneration research in mice has investigated Tβ4’s role in activating epicardial progenitor cells and promoting neovascularization following induced myocardial injury, contributing to a distinct angiogenesis-focused research thread within the broader Tβ4 literature.
Proposed Mechanism of Action
The literature converges on a few proposed mechanisms rather than one confirmed pathway. First, as an actin-binding/sequestering protein, Tβ4 is proposed to promote migration of endothelial cells, keratinocytes, and corneal epithelial cells to injury sites without necessarily increasing overall cell proliferation, based on in-vitro migration assays cited in the ophthalmology review. Second, in ligament studies, researchers propose that Tβ4 supports more organized collagen fibrillogenesis during the granulation phase of repair, contributing to the improved biomechanical outcomes observed in the MCL rat model. Third, anti-inflammatory and anti-apoptotic activity has been proposed based on reduced inflammatory markers and cell death observed in treated corneal tissue. As with BPC-157, these mechanisms are derived from animal and cell-culture models, and the full human pharmacodynamic profile remains an active research question.
Research Use Only / Handling Note
Supplied as a lyophilized powder for laboratory research applications only. Not intended for human or veterinary administration, and not a finished pharmaceutical product.